ArticleAsian Pacific journal of cancer prevention : APJCP2021
Lung Cancer Survival with Current Therapies and New Targeted Treatments: A Comprehensive Update from the Srinagarind Hospital-Based Cancer Registry from (2013 to 2017).
Article in Asian Pacific journal of cancer prevention : APJCP, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials.Frontiers in immunology · 2024Pooled it
- The Impact of the COVID-19 Pandemic on Diagnosis, Treatment, and Survival of Lung Cancer Patients in Thailand from 2019-2021.Journal of clinical medicine · 2026Article
- Concordance study of bronchial biopsy tissues and matched bronchial brushing cytology specimens in driver gene detection of non-small cell lung cancer.Frontiers in oncology · 2026Article
- The B-cell-autoantibody axis in lung cancer immunity.Theranostics · 2026Review
- PTPRC is an immunotherapeutic predictor and serum biomarker in lung adenocarcinoma correlated with immune cell infiltration.Scientific reports · 2025Article
- Expert recommendations for biomarker evaluation of advanced non-small cell lung cancer in Thailand.Translational lung cancer research · 2025Review
- Cuproptosis: a novel therapeutic mechanism in lung cancer.Cancer cell international · 2025Review
- Biomarker-Specific Survival and Medication Cost for Patients With Non-Small Cell Lung Cancer.JAMA network open · 2025Article
- Role and Therapeutic Potential of P2X7 Receptor in Lung Cancer Progression.Current medicinal chemistry · 2025Review
- Article
- The Ligurian Experience in the Management of Lung Cancer: Organizational Models and New Perspectives.Healthcare (Basel, Switzerland) · 2024Article
- Healthcare disparities, screening, and molecular testing in the changing landscape of non-small cell lung cancer in the United States: a review.Cancer metastasis reviews · 2024Review
- Overexpression of CDCA8 predicts poor prognosis and drug insensitivity in lung adenocarcinoma.BMC medical genomics · 2024Article
- Metformin is a potential therapeutic for COVID-19/LUAD by regulating glucose metabolism.Scientific reports · 2024Article
- A novel microRNA miR-4433a-3p as a potential diagnostic biomarker for lung adenocarcinoma.Heliyon · 2024Article
- Up-regulated ORC1 promotes lung adenocarcinoma by inhibiting ferroptosis via SLC7A11 dependent pathway.Heliyon · 2024Article
- Characteristics and patient-reported outcomes of long-term lung cancer survivors.Journal of thoracic disease · 2024Article
- Article
- Survival Analysis of Lung Cancer: A 10-Year Real-Life Experience in a Non-University-Based Hospital in Thailand (2012-2021).Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer (LC) is a common malignancy and leading cause of cancer death worldwide and in Thailand. An update on LC survival factors after diagnosis at Srinagarind Hospital is needed.
methodsWe conducted a retrospective cohort study, and the data were sourced from the Srinagarind Hospital-Based Cancer Registry. All LC cases were diagnosed between January 1, 2013, and December 31, 2017, and followed up until November 30, 2019. Cases of LC (ICD-O-3) numbered 2,149, but only those with coding C34.0-C34.9 were included. The survival rate was estimated using Kaplan-Meier, while the Log-rank test was used to estimate survival. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazard regression models.
resultsThe 2,149 patients had a total follow-up of 269.6 person-years. Overall, 1,867 patients died during the study, for a corresponding case-fatality mortality rate of 86.0 per 100 person-years. The respective 1-, 3-, and 5-year survival rate was 31.2 % (95% CI; 29.21 to 33.15%), 12.9 % (95%CI: 11.49 to 14.45), and 10.2% (95%CI: 8.74 to 11.70). After patient diagnosis, the median survival time was 0.46 years (5.51 months) (95% CI: 0.42 to 0.50). Targeted therapy was associated with longer survival than non-targeted therapy (p-value < 0.001). After adjusting for sex, TNM stage, and histologic type, multivariable analysis of the entire cohort identified chemotherapy as an independent predictor of improved survival (adjusted HR= 0.48; 95% CI: 0.42 to 0.55; P < 0.001), and that sex, TNM stage, and histologic type were associated with survival.
conclusionThe study confirmed that sex, stage of disease, histology, and chemotherapy are associated with survival of LC. Primary prevention and screening for early detection improve survival. Further investigations into factors affecting survival of LC in Northeast Thailand should focus on targeted therapy.<br />.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.